Get the Stockscreener App
10.75
1.70%
0.18
After Hours:
10.75
Olema Pharmaceuticals Inc stock is traded at $10.75, with a volume of 600.14K.
It is up +1.70% in the last 24 hours and up +38.35% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$10.57
Open:
$10.58
24h Volume:
600.14K
Relative Volume:
0.70
Market Cap:
$737.82M
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-5.00
EPS:
-2.15
Net Cash Flow:
$-83.73M
1W Performance:
-2.80%
1M Performance:
+38.35%
6M Performance:
+185.15%
1Y Performance:
-8.43%
1-Day Range:
$10.28
$10.94
1-Week Range:
$10.23
$11.34
52-Week Range:
$2.86
$13.51
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
10.75 | 725.46M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-12-25 | Reiterated | Citigroup | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Using flow based indicators on Olema Pharmaceuticals Inc.Earnings Recap Report & Technical Analysis for Trade Confirmation - newser.com
Has Olema Pharmaceuticals Inc. found a price floorJuly 2025 Big Picture & Stepwise Entry and Exit Trade Signals - newser.com
Institutional scanner results for Olema Pharmaceuticals Inc.July 2025 PostEarnings & AI Based Buy/Sell Signal Reports - newser.com
Published on: 2025-10-13 10:23:49 - newser.com
How sustainable is Olema Pharmaceuticals Inc. stock dividend payoutJuly 2025 Levels & Low Drawdown Momentum Ideas - newser.com
Why Olema Pharmaceuticals Inc. stock attracts global investorsWeekly Earnings Recap & Fast Exit/Entry Strategy Plans - newser.com
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Up 5.7%What's Next? - MarketBeat
Visual trend scoring systems applied to Olema Pharmaceuticals Inc.2025 Major Catalysts & Fast Exit and Entry Strategy Plans - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Olema Pharmaceuticals (NASDAQ:OLMA) - MarketBeat
Can momentum traders help lift Olema Pharmaceuticals Inc.2025 Performance Recap & Fast Momentum Entry Tips - newser.com
Guggenheim Begins Coverage on Olema Pharmaceuticals (NASDAQ:OLMA) - Defense World
Does Olema Pharmaceuticals Inc. fit your quant trading modelEarnings Risk Summary & Risk Controlled Swing Trade Alerts - newser.com
Is now a turning point for Olema Pharmaceuticals Inc.2025 Growth vs Value & Consistent Income Trade Recommendations - newser.com
Will Olema Pharmaceuticals Inc. benefit from macro trendsMarket Growth Review & Fast Exit and Entry Trade Guides - newser.com
Farther Finance Advisors LLC Grows Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA - Defense World
Guggenheim Initiates Coverage on OLMA with a 'Buy' Rating and $2 - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Earns Buy Rating from Analysts at Guggenheim - MarketBeat
Guggenheim initiates coverage on Olema Pharmaceuticals stock with Buy rating - Investing.com
Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Target Price at $24.00 - Defense World
What analysts say about Olema Pharmaceuticals Inc stockAnalyst Upgrades & Low Cost Portfolio Ideas - earlytimes.in
How moving averages guide Olema Pharmaceuticals Inc. tradingStop Loss & Stock Portfolio Risk Control - newser.com
How analysts rate Olema Pharmaceuticals Inc. stock todayEarnings Growth Report & Expert Verified Movement Alerts - newser.com
Will Olema Pharmaceuticals Inc. stock deliver better than expected guidanceQuarterly Profit Review & Step-by-Step Swing Trade Plans - newser.com
How to forecast Olema Pharmaceuticals Inc. trends using time seriesJuly 2025 Spike Watch & Weekly Chart Analysis and Trade Guides - newser.com
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Metastatic HR+/HER2− Breast Cancer Market Positioned For Accelerated Development Through 2034, Delveinsight Finds Novartis, Arvinas, Olema Pharma, Sichuan Baili Pharma, Ana C Garrido-Castro - Menafn.com
Metastatic HR+/HER2− Breast Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Arvinas, Olema Pharma, Sichuan Baili Pharma, Ana C Garrido-Castro - Barchart.com
Metastatic HR+/HER2 Breast Cancer Market Positioned - openPR.com
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Chart based exit strategy for Olema Pharmaceuticals Inc.Watch List & Stepwise Entry and Exit Trade Signals - newser.com
Cancer stocks rebound, outpacing broader markets in Q3 2025 - BioWorld MedTech
77,000-share award: Olema Pharmaceuticals grants stock options at $11.04 as inducement - Stock Titan
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 6.3%Time to Sell? - MarketBeat
Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA) - Insider Monkey
11 Best Fast Money Stocks to Buy Now - Insider Monkey
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Olema Pharmaceuticals Inc Stock (OLMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Harmon Cyrus | Director |
Sep 16 '25 |
Sale |
8.04 |
10,000 |
80,400 |
754,140 |
| Harmon Cyrus | Director |
Sep 18 '25 |
Sale |
8.32 |
3,086 |
25,676 |
117,028 |
| Harmon Cyrus | Director |
Sep 16 '25 |
Sale |
8.08 |
1,914 |
15,465 |
120,114 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):